Partnership formed for vision restoration

Article

The Max Planck Society (Max-Planck-Gesellschaft) and Fovea Pharmaceuticals (the ophthalmology division of Sanofi) have announced the formation of a partnership to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

The Max Planck Society (Max-Planck-Gesellschaft) and Fovea Pharmaceuticals (the ophthalmology division of Sanofi) have announced the formation of a partnership to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

This research collaboration and licence agreement will last for 3 years and will see the Fovea team work with the Max Planck Institute of Biophysics, led by Professor Ernst Bamberg, who pioneered the understanding of the application of retinal binding channelrhodopsins and was one of the founders of optogenetics. Professor Bamberg commented, "The cooperation is a big step forward to bring the optogenetic approach to the clinics."

The agreement will complement other collaborations of Fovea and will further advance research on the retinal binding protein channelrhodopsin 2 (ChR2) and its application in retinal diseases. It is hoped that a successful outcome of this research will result in restoration of visual function in patients suffering from reduced vision or blindness.

Under the terms of the agreement the Max Planck Institute will receive a total of €450,000 and Sanofi will be given priority access to the technology, inventions and derived technologies of the Max Planck Institute research activities in ChR2.

For more information visit the Max Planck Society's website at www.mpg.de

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.